Io Biotech Intrinsic Value Calculation – Insiders Lose an Additional US$8.5k as IO Biotech,’s Stock Sinks 10% in 2023.
March 26, 2023
Trending News 🌧️
Investors in IO ($NASDAQ:IOBT) Biotech, Inc. have been dealt a major blow this year with the stock price now standing at US$1.98, a 10% decrease since the start of the year. The sharp drop in price is sure to be a disappointment for those who had high hopes for the stock. IO Biotech, Inc. had been tipped to be a strong performer this year, with many analysts expecting positive returns for shareholders. Unfortunately, the reality is that the stock has dropped significantly in value, leaving insiders out of pocket and unsure what to do next.
The situation is made worse by the fact that there have been no major announcements from IO Biotech, Inc., suggesting that the decrease in price is merely a result of general market forces. While the future remains uncertain, it is clear that those who had purchased IO Biotech, Inc. shares earlier this year have lost out significantly due to the recent drop in price.
Market Price
The news sentiment surrounding IO Biotech, Inc. has been mostly negative in recent weeks. On Friday, IO Biotech’s stock opened at US$2.0 and closed at US$2.0, up by 1.0% from the previous closing price of US$2.0. Despite the small increase, insiders have lost an additional US$8.5k as the stock has sunk 10% since the beginning of the year. However, investors are hopeful that the company can turn things around and make a successful recovery in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Io Biotech. More…
| Total Revenues | Net Income | Net Margin |
| 0 | -71.46 | – |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Io Biotech. More…
| Operations | Investing | Financing |
| -59.73 | -0.69 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Io Biotech. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 151.81 | 12.95 | 4.82 |
Key Ratios Snapshot
Some of the financial key ratios for Io Biotech are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | – |
| FCF Margin | ROE | ROA |
| – | -29.9% | -28.8% |
Analysis – Io Biotech Intrinsic Value Calculation
At GoodWhale, we conducted an in-depth analysis of IO BIOTECH’s fundamentals. Our proprietary Valuation Line shows that the fair value of IO BIOTECH’s shares is around $3.9. Currently, IO BIOTECH’s share price is around $2.0, which means the stock is undervalued by 48.3%. This presents a good investment opportunity for investors who are looking to buy undervalued stocks. More…
Peers
Biotech companies are developing innovative new therapies to treat a variety of diseases. IO Biotech Inc is one such company, and its competitors Larimar Therapeutics Inc, Aura Biosciences Inc, and Annexon Inc are also working on cutting-edge treatments.
– Larimar Therapeutics Inc ($NASDAQ:LRMR)
Larimar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat patients with rare diseases. The company has a market cap of 149.28M as of 2022 and a Return on Equity of -73.95%. Larimar is currently developing two lead candidates: LT-300, for the treatment of alpha-1 antitrypsin deficiency, and LT-200, for the treatment of primary ciliary dyskinesia.
– Aura Biosciences Inc ($NASDAQ:AURA)
Aura Biosciences Inc is a clinical stage biopharmaceutical company. The company is engaged in developing and commercializing of pharmaceutical products based on its proprietary technology for the treatment of cancer and other serious diseases. Its market cap as of 2022 is 391.97M and ROE is -21.81%. The company’s product pipeline includes Aura-CLS, Aura-LV, and Aura-AO. Aura-CLS is in Phase I/II clinical trials for the treatment of cutaneous T-cell lymphoma (CTCL). Aura-LV is in Phase I/II clinical trials for the treatment of relapsed or refractory B-cell lymphoma. Aura-AO is in Phase I/II clinical trials for the treatment of acute myeloid leukemia (AML).
– Annexon Inc ($NASDAQ:ANNX)
Annexon Inc is a company that focuses on developing therapies for autoimmune diseases and other inflammatory conditions. The company has a market capitalization of 260.95 million as of 2022 and a return on equity of -35.03%. The company has been facing some financial difficulties recently, which has led to its market capitalization and return on equity declining. However, the company is still working on developing new therapies that could help improve the lives of patients with autoimmune diseases and other inflammatory conditions.
Summary
IO Biotech, Inc. has seen its stock value drop by 10% in 2023, resulting in a financial loss of US$8.5k for its investors. This has caused a negative sentiment in the market and has investors questioning their decision to invest in the company. Despite the current downturn, it is important to analyze the company’s financial information and market movements to get a better understanding of the investment prospects of IO Biotech, Inc. Investors should evaluate the company’s financial statements, such as its balance sheet, income statement, cash flow statement, and other documents.
Additionally, investors should monitor trends in the industry and the overall market, to determine IO Biotech, Inc’s performance relative to competitors. Analyzing the company’s management team, and assessing potential risks are also important steps when considering an investment. As always, investors should do their due diligence before investing in any company.
